A federal pricing pact with Pfizer and an executive order on pediatric cancer AI may reshape affordability and evidence pathways for pharmacists and patients.
Reyaz Mussaleen, PharmD Candidate
Advertisement
Articles by Reyaz Mussaleen, PharmD Candidate
Antibody-drug conjugates (ADCs) revolutionize cancer therapy by delivering powerful drugs directly to tumors and minimize damage to healthy cells.
Advertisement
Latest Updated Articles
Policy Update: Pfizer Pricing and Pediatric Cancer AIPublished: October 1st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of Invasive Fungal Infections Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
5
